Summary :
Glenmark Pharmaceuticals on Monday said its subsidiary has inked a pact to commercialise AstraZeneca’s asthma drug Pulmicort Respules in the Colombian market.
Glenmark Pharmaceuticals Colombia SAS and AstraZeneca Colombia have entered into an exclusive licensing agreement
Glenmark Pharmaceuticals Colombia SAS and AstraZeneca Colombia have entered into an exclusive licensing agreement for the commercialization of AstraZeneca’s Pulmicort Respules, the Mumbai-based drug maker said in a statement.
Under the terms of the agreement, AstraZeneca remains the holder of the registration for Pulmicort Respules and will be responsible for manufacturing and supplying the drug while Glenmark will be responsible for its commercialisation in the Colombian market, it added.
Glenmark Pharmaceuticals Executive Vice President and Global Head – Business Development Marco Cerato noted that the partnership would help in strengthening the company’s key therapy area of respiratory medicine in the region.
Genmark currently markets a range of respiratory drugs in Latin America including Glemont L, Glencet Levocetirizine and Furomet. PTI MSS RUJ RUJ
About Glenmark Pharmaceutical
Glenmark Pharmaceuticals Limited is an Indian pharmaceutical company headquartered in Mumbai, India that was founded in 1977 by Gracias Saldanha as a generic drug and active pharmaceutical ingredient manufacturer; he named the company after his two sons.
Some product
- Asar-CT 40/12.5 Tablet.
- Airtec FB 200 Instacap.
- Airtec FB 400 Inhaler.
- Airtec FB 400 Instacap.
- Airtec SF 250 Instacap.
- Airtec SF 50 mcg/250 mcg Inhaler.
- Airz Capsule.
- Airz-F Capsule.
